InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (2 ops.)
Insider track record
CEODisclosed buys
1
Disclosed sells
2
T+90 hit rate
0%
T+90 mean return
-23.2%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Klausner Richard, Président Exécutif. Director active across 2 companies, notably Lyell Immunopharma, Inc.. In total, 6 reports have been published. Split: 1 buy · 2 sells. Total volume traded: €281k. History available since 23 September 2022. The latest transaction was filed on 14 March 2025 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Declarations6 total
158,000 shares@ US$0.600931.1% of flowCommon StockSEC:0001415889-25-008540:0
Canonical exit: 12 Jun 2025 (T+90)
58,020 shares@ US$2.2843.2% of flowCommon StockSEC:0001209191-23-046267:0
11,100 shares@ US$6.400125.7% of flowCommon StockSEC:0001209191-22-051379:0
3,765,842 sharesCommon StockSEC:0001209191-21-042798
3,765,842 sharesCommon StockSEC:0001209191-21-042798:0
253 sharesCommon StockSEC:0001127602-16-038840:0
6 of 6 declarations
About Klausner Richard
Richard Klausner is the Executive Chairman of Lyell Immunopharma, Inc. He plays a key role in the strategic direction of the company, bringing his expertise in biotechnology and drug development. His role as a board member includes overseeing performance and evaluating initiatives aimed at enhancing innovation and research. He ensures that Lyell Immunopharma meets its performance and innovation objectives.
